Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Preoperative short course radiotherapy with concurrent and consolidation chemotherapies followed by delayed surgery in locally advanced rectal cancer: preliminary results

  • Aghili, Mahdi (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Sotoudeh, Sarvazad (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Ghalehtaki, Reza (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Babaei, Mohammad (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Farazmand, Borna (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Fazeli, Mohammad-Sadegh (Colorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences) ;
  • Keshvari, Amir (Colorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences) ;
  • Haddad, Peiman (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Farhan, Farshid (Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences)
  • Received : 2017.04.05
  • Accepted : 2017.10.30
  • Published : 2018.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to assess complications and outcomes of a new approach, that is, combining short course radiotherapy (SRT), concurrent and consolidative chemotherapies, and delayed surgery. Materials and Methods: In this single arm phase II prospective clinical trial, patients with T3-4 or N+ M0 rectal adenocarcinoma were enrolled. Patients who received induction chemotherapy or previous pelvic radiotherapy were excluded. Study protocol consisted of three-dimensional conformal SRT (25 Gy in 5 fractions in 1 week) with concurrent and consolidation chemotherapies including capecitabine and oxaliplatin. Total mesorectal excision was done at least 8 weeks after the last fraction of radiotherapy. Primary outcome was complete pathologic response and secondary outcomes were treatment related complications. Results: Thirty-three patients completed the planned preoperative chemoradiation and 26 of them underwent surgery (24 low anterior resection and 2 abdominoperineal resection). Acute proctitis grades 2 and 3 were seen in 11 (33.3%) and 7 (21.2%) patients, respectively. There were no grades 3 and 4 subacute hematologic and non-hematologic (genitourinary and peripheral neuropathy) toxicities and perioperative morbidities such as anastomose leakage. Grade 2 or higher late toxicities were observed among 29.6% of the patients. Complete pathologic response was achieved in 8 (30.8%) patients who underwent surgery. The 3-year overall survival and local control rates were 65% and 94%, respectively. Conclusion: This study showed that SRT combined with concurrent and consolidation chemotherapies followed by delayed surgery is not only feasible and tolerable without significant toxicity but also, associated with promising complete pathologic response rates.

Keywords

References

  1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40. https://doi.org/10.1056/NEJMoa040694
  2. Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma: a prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 1995;75:2269-75. https://doi.org/10.1002/1097-0142(19950501)75:9<2269::AID-CNCR2820750913>3.0.CO;2-I
  3. Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B; Stockholm Colorectal Cancer Study Group. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 2001;92:896-902. https://doi.org/10.1002/1097-0142(20010815)92:4<896::AID-CNCR1398>3.0.CO;2-R
  4. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30:3827-33. https://doi.org/10.1200/JCO.2012.42.9597
  5. Farhan F, Fazeli MS, Samiei F, et al. Morbidity and mortality following short course preoperative radiotherapy in rectal carcinoma. Acta Med Iran 2015;53:627-32.
  6. Minsky BD. Short-course radiation versus long-course chemoradiation for rectal cancer: making progress. J Clin Oncol 2012;30:3777-8. https://doi.org/10.1200/JCO.2012.45.0551
  7. Bujko K, Partycki M, Pietrzak L. Neoadjuvant radiotherapy (5 $\times$ 5 Gy): immediate versus delayed surgery. Recent Results Cancer Res 2014;203:171-87.
  8. Myerson RJ, Parikh PJ, Tan B, et al. A single-institution phase II trial of five fractions of radiotherapy followed by four courses of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma. J Clin Oncol 2012;30(4_Suppl):553. https://doi.org/10.1200/jco.2012.30.4_suppl.553
  9. Chung MJ, Kim DW, Chung WK, et al. Preoperative short- vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer. Oncotarget 2016;8:60479-86.
  10. Rasulov AO, Gordeyev SS, Barsukov YA, et al. Short-course preoperative radiotherapy combined with chemotherapy, delayed surgery and local hyperthermia for rectal cancer: a phase II study. Int J Hyperthermia 2017:1-9.
  11. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824-30. https://doi.org/10.1016/j.ijrobp.2008.08.070
  12. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. https://doi.org/10.1007/s003840050072
  13. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010;97:580-7. https://doi.org/10.1002/bjs.6914
  14. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-23. https://doi.org/10.1002/bjs.5506
  15. Ansari N, Solomon MJ, Fisher RJ, et al. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). Ann Surg 2017;265:882-8. https://doi.org/10.1097/SLA.0000000000001987
  16. Beppu N, Matsubara N, Kakuno A, et al. Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer. Dis Colon Rectum 2015;58:479-87. https://doi.org/10.1097/DCR.0000000000000323
  17. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017;18:336-46. https://doi.org/10.1016/S1470-2045(17)30086-4
  18. van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of shortcourse radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013;24:1762-9. https://doi.org/10.1093/annonc/mdt124
  19. Beppu N, Yoshie H, Kimura F, et al. The short-term outcomes of induction SOX (S-1 + oxaliplatin) ${\pm}$ cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer. Surg Today 2016;46:1123-31. https://doi.org/10.1007/s00595-015-1284-2
  20. Yeo SG, Oh JH, Kim DY, et al. Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). Int J Radiat Oncol Biol Phys 2013;86:34-9. https://doi.org/10.1016/j.ijrobp.2012.11.018
  21. Lee JH, Kim JG, Oh ST, et al. Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02). Radiother Oncol 2014;110:150-4. https://doi.org/10.1016/j.radonc.2013.11.013
  22. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009;15:4806-14. https://doi.org/10.1158/1078-0432.CCR-09-0344
  23. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 2009;5:243-57. https://doi.org/10.1517/17425250902800153
  24. Hatfield P, Hingorani M, Radhakrishna G, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009;92:210-4. https://doi.org/10.1016/j.radonc.2009.04.007
  25. Kwak YK, Kim K, Lee JH, et al. Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: a multi-institutional study for optimal surgical timing in rectal cancer. Radiother Oncol 2016;119:512-8. https://doi.org/10.1016/j.radonc.2016.03.017
  26. Beppu N, Matsubara N, Noda M, et al. Short-course radiotherapy with delayed surgery versus conventional chemoradiotherapy: a comparison of the short- and longterm outcomes in patients with T3 rectal cancer. Surgery 2015;158:225-35. https://doi.org/10.1016/j.surg.2015.03.014
  27. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, Sao Juliao GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009;52:1927-34. https://doi.org/10.1007/DCR.0b013e3181ba14ed
  28. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5. https://doi.org/10.1200/JCO.2006.06.7629
  29. Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer: the RAPIDO trial. BMC Cancer 2013;13:279. https://doi.org/10.1186/1471-2407-13-279
  30. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-44. https://doi.org/10.1200/JCO.2009.25.8376
  31. Haddad P, Miraie M, Farhan F, et al. Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI-defined T3, T4 or N+ rectal cancer: a randomized clinical trial. Asia Pac J Clin Oncol 2017;13:416-22. https://doi.org/10.1111/ajco.12675
  32. van der Pols JC, Russell A, Bauer U, Neale RE, Kimlin MG, Green AC. Vitamin D status and skin cancer risk independent of time outdoors: 11-year prospective study in an Australian community. J Invest Dermatol 2013;133:637-41. https://doi.org/10.1038/jid.2012.346
  33. Yang YJ, Cao L, Li ZW, et al. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: an updated systematic review and meta-analysis. Oncotarget 2016;7:45513-24.
  34. Zheng J, Feng X, Hu W, Wang J, Li Y. Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer. Medicine (Baltimore) 2017;96:e6487. https://doi.org/10.1097/MD.0000000000006487

Cited by

  1. A Concise Review of Pelvic Radiation Therapy (RT) for Rectal Cancer with Synchronous Liver Metastases vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/5239042
  2. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial vol.9, pp.3, 2018, https://doi.org/10.1136/bmjopen-2018-025944
  3. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study vol.30, pp.8, 2019, https://doi.org/10.1093/annonc/mdz186
  4. Total Neoadjuvant Therapy in Rectal Cancer : A Systematic Review and Meta-analysis of Treatment Outcomes vol.271, pp.3, 2018, https://doi.org/10.1097/sla.0000000000003471
  5. The Evolving Landscape of Neoadjuvant Radiation Therapy for Locally Advanced Rectal Cancer vol.16, pp.3, 2020, https://doi.org/10.1007/s11888-020-00451-6
  6. Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial vol.38, pp.2, 2020, https://doi.org/10.3857/roj.2020.00115
  7. Radiotherapy and COVID-19: Practical recommendations from iran vol.149, pp.None, 2020, https://doi.org/10.1016/j.radonc.2020.04.051
  8. Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis vol.60, pp.10, 2021, https://doi.org/10.1080/0284186x.2021.1953137
  9. Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with s vol.39, pp.4, 2018, https://doi.org/10.3857/roj.2021.00654